Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the Lilly Medical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical

  1. Medical Information Right
  2. Diabetes Right
  3. Mounjaro (tirzepatide) injection Right
  4. Can Mounjaro® (tirzepatide) be used in people with autoimmune disorders?
Search Mounjaro (tirzepatide) injection (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Mounjaro ® (tirzepatide) injection

2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Can Mounjaro® (tirzepatide) be used in people with autoimmune disorders?

Tirzepatide has not been studied in people with significant and active autoimmune disorders. Eli Lilly and Company cannot provide treatment recommendations on the use of tirzepatide in people with these conditions.

US_cFAQ_TZP307_AUTOIMMUNE_DISORDERS_T2D_CWM
US_cFAQ_TZP307_AUTOIMMUNE_DISORDERS_T2D_CWMen-US

See important safety information, including boxed warning, in the attached prescribing information.

Tirzepatide Use in Patients With Autoimmune Disorders

No information is available on the use of tirzepatide in patients with significant and active autoimmune abnormalities such as, but not limited to, lupus, multiple sclerosis, or rheumatoid arthritis. Participants were excluded from clinical trials if they were receiving, or likely to require systemic glucocorticoids during the course of the study.1-9

Clinical Considerations 

Eli Lilly and Company cannot provide treatment recommendations on the use of tirzepatide in patients with a history of a significant and active autoimmune disorder. In formulating an assessment and approach, the health care practitioner may consider

  • the information provided
  • the patient’s prior medical history and concomitant medications, and
  • other individual factors.

The health care practitioner should consider potential risks and benefits of treatment options and monitor appropriately.

Tirzepatide Studies in Psoriatic Arthritis and Plaque Psoriasis (TOGETHER-PsA and TOGETHER-PsO)

The efficacy and safety of ixekizumab and ixekizumab concomitantly administered with tirzepatide is being evaluated in two phase 3b studies in adult participants (≥18 years of age) with obesity or overweight and

  • active psoriatic arthritis (TOGETHER-PsA), or 
  • moderate-to-severe plaque psoriasis (TOGETHER-PsO).10-12

There are no available safety data on the use of ixekizumab with concomitantly administered tirzepatide.12

Enclosed Prescribing Information

MOUNJARO® (tirzepatide) injection, for subcutaneous use, Lilly

TALTZ® (ixekizumab) injection, for subcutaneous administration, Lilly

References

The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).

1Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155. https://doi.org/10.1016/S0140-6736%2821%2901324-6

2Frías JP, Davies MJ, Rosenstock J, et al; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. https://doi.org/10.1056/NEJMoa2107519

3Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583-598. https://doi.org/10.1016/S0140-6736(21)01443-4

4Del Prato S, Kahn SE, Pavo I, et al; SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811-1824. https://doi.org/10.1016/S0140-6736(21)02188-7

5Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534-545. https://doi.org/10.1001/jama.2022.0078

6Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. https://doi.org/10.1056/NEJMoa2206038

7Garvey WT, Frias JP, Jastreboff AM, et al; SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. https://doi.org/10.1016/S0140-6736(23)01200-X

8Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2909-2918. https://doi.org/10.1038/s41591-023-02597-w

9Aronne LJ, Sattar N, Horn DB, et al; SURMOUNT-4 Investigators. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. https://doi.org/10.1001/jama.2023.24945

10Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight (TOGETHER-PsA). ClinicalTrials.gov identifier: NCT06588296. Updated April 3, 2025. Accessed April 10, 2025. https://clinicaltrials.gov/study/NCT06588296

11Ixekizumab concomitantly administered with tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight (TOGETHER-PsO). ClinicalTrials.gov identifier: NCT06588283. Updated February 27, 2025. Accessed April 10, 2025. https://clinicaltrials.gov/study/NCT06588283

12Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Date of Last Review: March 12, 2025

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.44 4/2025 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2025. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
    Cookie Settings
    facebook twitter linkedin
    visit www.phactmi.org
    Lilly